Resources Management Corp CT ADV bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, Holdings Channel.com reports. The fund bought 64,858 shares of the biopharmaceutical company’s stock, valued at approximately $3,289,000.
A number of other hedge funds have also modified their holdings of BMY. Garrett Wealth Advisory Group LLC purchased a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC raised its position in shares of Bristol-Myers Squibb by 555.7% during the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. raised its position in shares of Bristol-Myers Squibb by 101.2% during the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 327 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 230 shares in the last quarter. Finally, 1 North Wealth Services LLC purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth $41,000. Institutional investors and hedge funds own 83.01% of the company’s stock.
Several equities analysts recently weighed in on BMY shares. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Wolfe Research set a $66.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, September 13th. Finally, Gabelli assumed coverage on Bristol-Myers Squibb in a research report on Wednesday, November 27th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $57.95.
BMY traded up $1.15 during trading hours on Wednesday, hitting $58.90. The company’s stock had a trading volume of 21,668,416 shares, compared to its average volume of 24,667,110. The stock has a market cap of $92.77 billion, a price-to-earnings ratio of 14.80, a P/E/G ratio of 1.32 and a beta of 0.70. The business’s 50-day moving average price is $56.18 and its 200-day moving average price is $49.50. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $59.17.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. During the same quarter last year, the business earned $1.09 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb Co will post 4.38 earnings per share for the current year.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.